MFDS Approves Alteogen Recombinant Hyaluronidase Phase 1 Clinical Trial
[Asia Economy Reporter Ji Yeon-jin] Alteogen announced on the 16th that the Ministry of Food and Drug Safety approved the Phase 1 clinical trial plan to evaluate the safety, tolerability, and pharmacokinetic characteristics of 'ALT-BB4 (Terzyme, recombinant hyaluronidase)' in healthy adults.
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Russian Foreign Ministry "Hopes for Visit by North Korean Foreign Minister Choe Son Hui This Year"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.